DexCom stock has been a mixed picture for investors. The San Diego-based medical technology company has beaten Wall Street expectations and beaten the broader healthcare sector so far this year. But over the last 52 weeks, it has lagged behind a key industry benchmark. The question is whether DXCM is underperforming the healthcare sector or simply catching its breath.
Reading the DXCM Numbers
DexCom, Inc. (DXCM) is a pioneer in continuous glucose monitoring, or CGM, systems that give people with diabetes real-time glucose data. The company carries a market capitalization of $33.2 billion, placing it firmly in the “large-cap” category of stocks worth between $10 billion and $200 billion.
The stock has climbed 32.4% year-to-date. That significantly outperforms the State Street Health Select Sector SPDR ETF (XLV), which has gained 10.8% over the same period.
But the longer view tells a different story. Over the past 52 weeks, DXCM has gained 8.8%, underperforming the ETF’s 24.8% return. The stock has also slipped 5.1% from its 52-week high, reached on August 24, 2026.
Over the past three months, DXCM has climbed 21.1%, again outpacing XLV’s 12.7% gain.
What the Q2 Report Showed
A major catalyst came on July 31, when DXCM shares surged about 12% after reporting its Q2 results. The company’s revenue rose 13.1% year over year to $1.31 billion, beating Wall Street forecasts of $1.29 billion. Non-GAAP net income per share of 70 cents also surpassed expectations of 61 cents.
The stock has been trading above its 50-day and 200-day moving averages since mid-May, signaling an upward trend.
DexCom’s competitive edge lies in its CGM technology and its reputation for accuracy and reliability. Its systems integrate with insulin pumps, and the company’s revenue growth, improving profitability, and strong cash position give it flexibility to invest in innovation.
Abbott and the Analyst View
In the healthcare sector, top rival Abbott Laboratories (ABT) has considerably outperformed DXCM, gaining 18.4% over the past year.
Wall Street analysts remain bullish on DXCM’s prospects. The stock has a consensus “Strong Buy” rating from the 29 analysts covering it. The mean price target of $93.11 suggests potential upside of 5.9% from current price levels.
The article was published on Barchart.com, where author Kritika Sarmah disclosed that she did not have positions, either directly or indirectly, in any of the securities mentioned.
A Mixed Picture for Investors
The picture is not simple. DXCM has beaten the healthcare sector over three months and year-to-date, but lagged over 52 weeks. The strong Q2 report and the recent upward trend suggest momentum. The longer-term underperformance against both XLV and Abbott shows the competition is real.
For investors, the analysts’ “Strong Buy” consensus and the mean price target above the current level point to continued confidence. Whether DXCM can close the 52-week gap against the sector will depend on sustained revenue growth and execution in a competitive CGM market.
The stock is down from its high but moving in the right direction.
Key Facts
- Market cap: $33.2 billion
- 52-week high reached August 24, 2026
- Stock down 5.1% from high
- Three-month gain: 21.1% vs. XLV’s 12.7%
- Year-to-date gain: 32.4% vs. XLV’s 10.8%
- 52-week gain: 8.8% vs. XLV’s 24.8%
- Q2 revenue: $1.31 billion, up 13.1% year over year
- Q2 non-GAAP EPS: 70 cents vs. 61 cents expected
- Analyst rating: “Strong Buy” from 29 analysts
- Mean price target: $93.11
Source: finance.yahoo.com
Get the Notebook.
The day's best stories and every fresh verdict, in plain English, in your inbox by seven. One email a day, no more.